Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DA-007
- Development stage
- Phase 3
- Lead developer
- Jupiter Wellness
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
DA-007 is a small molecule drug under development for the treatment of chemotherapy-induced alopecia. It is being developed by Applied Biology and is currently in Phase 3 clinical trials. The proposed mechanism of action involves reducing scalp blood perfusion, which may help to decrease hair loss associated with chemotherapy. The precise molecular target and detailed mechanism remain unknown.
Beyond the preview
Go deeper on DA-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DA-007.